China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
A global shift may be underway in biopharma as the White House prepares legislation that would would place restrictions on drugs brought to the U.S. from China, and pharma companies exit the U.K. in droves. President Donald Trump is reportedly writing an executive order that would clamp down on the pharmaceutical industry’s ability to buy new molecules from biotechs based in China, while Sanofi, Merck and more have canceled or suspended investments in the U.K. following a sizeable increase in a mandatory levy in the region.
In other business news, Novo Nordisk’s newly appointed CEO Maziar…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.